Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia
Corveleyn, L.; Provez, L.; Satilmis, O.; Refhagen, N.; Landfors, M.; Sleeckx, W.; Lintermans, B.; De Maesschalck, A.; Kotecha, R. S.; De Moerloose, B.; Lammens, T.; Deforce, D.; Degerman, S.; Goossens, S.; Van Vlierberghe, P.; Dhaenens, M.
Show abstract
Epigenetic modifications are dynamic and reversible, making them attractive targets for therapeutic intervention in cancer. Although several epigenetic drugs (epidrugs) have been clinically approved, their application in T-cell acute lymphoblastic leukemia (T-ALL) remains limited, and predictive biomarkers of response are lacking. Here, we present a mass spectrometry (MS)-based pharmacoepigenetic approach to profile histone post-translational modifications (hPTMs) to identify signatures associated with epidrug sensitivity in T-ALL. Baseline hPTM landscapes were previously established by our group for 21 T-ALL cell lines using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Here, we treated these cell lines with a panel of nine epidrugs including anthracyclines, histone deacetylase inhibitors, and DNA methyltransferase inhibitors. Correlation of cell viability data with hPTM levels revealed distinct hPTM signatures linked to sensitivity for each drug class. These signatures were subsequently evaluated in T-ALL patient-derived xenograft (PDX) models. However, we our analysis revealed substantial discepancies in hPTM sensitivity signatures compared to those observed in vitro. Co-variation network analysis highlighted divergence in hPTM-hPTM correlation between the two models, underscoring limitations of cell lines for modeling dynamic epigenetic regulation in vivo. Our findings establish a framework for MS-based hPTM profiling in T-ALL and emphasize the importance of model selection in developing predictive epigenetic biomarkers. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/673463v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@1b15092org.highwire.dtl.DTLVardef@20bed5org.highwire.dtl.DTLVardef@1d0a687org.highwire.dtl.DTLVardef@1652999_HPS_FORMAT_FIGEXP M_FIG C_FIG Global hPTM profiling of 21 T-ALL cell lines was performed using LC-MS/MS, as previously published by Provez et al. In parallel, the 21 cell lines were treated with a dilution series of nine epidrugs, categorized into three distinct classes, to determine their IC50 values. Finally, Spearman correlation analysis was performed to assess the relationship between hPTM levels and drug sensitivity. Figure created with Biorender.com.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia 95%
- Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy 94%
- In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets 94%
Similar papers in this journal
- Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core 95%
- Mapping AML heterogeneity – multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses 95%
- Base edited "universal" donor CAR T cell strategies for acute myeloid leukaemia 94%
Similar papers in this journal
- ATP citrate lyase is an essential player of the metabolic rewiring induced by PTEN loss during T-ALL development. 96%
- Resistance mechanism to Notch inhibition and combination therapy in human T cell acute lymphoblastic leukemia 96%
- Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma 95%
Similar papers in this journal
- Ex Vivo Drug Responses and Molecular Profiles of 597 Pediatric Acute Lymphoblastic Leukemia Patients 96%
- Linker histone H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape 94%
- NOTCH1 fusions in pediatric T-cell lymphoblastic lymphoma: a high-risk subgroup with CCL17 (TARC) levels as diagnostic biomarker 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.